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Objectives. Dysbetalipoproteinaemia (type III hyperlipi-
daemia, broad-beta disease) is a highly atherogenic genetic 
disorder of lipoprotein metabolism. It presents with a 
severe mixed hyperlipidaemia in which the ratio of total 
cholesterol to triglycerides is typically 2:1. There is a high 
incidence of atherosclerotic complications and severe 
hypertriglyceridaemia may cause pancreatitis. Highly 
effective therapy is available and affected families also 
benefit from genetic counselling. 
We present a review of our experience with 
dysbetalipoproteinaemia at the lipid clinic of Groote Schuur 
Hospital to enhance awareness of this serious condition, for 
which the index of suspicion should be raised. 
Design. Retrospective review of case records, 1969- 2001. 
Setting. Lipid clinic of Groote Schuur Hospital, Cape Town. 
Subjects. Patients with dysbetalipoproteinaemia diagnosed 
by the presence of cholesterol-enriched very-low-density 
lipoproteins (VLDL) and/or dyslipidaemia associated with 
homozygosity for apolipoprotein E2 or carriers of the 
apoE2 (Arg145~Cys) mutation. 
Results. One hundred and five patients were identified, 55 
of whom were male and 50 female. The age at presentation 
was 48.8 ± 11.1 years (mean, standard deviation). Total 
cholesterol was 12.0 ± 5.5 mmol/l and plasma triglycerides 
8.3 ± 9.8 mmol/1. The ratio (by mass) of cholesterol to 
triglycerides within VLDL was 0.52 ± 0.17, while VLDL 
cholesterol to plasma triglycerides was 0.33 ± 0.09. Fifty 
patients were E2 homozygotes while 22 carried the apoE2 
(Arg145~Cys) mutation. Palmar crease xanthomas 
occurred in 20% of patients, cutaneous xanthomas in 18%, 
and tendon xanthomas in 13%. Coronary artery disease was 
found in 47% of patients and peripheral vascular disease in 
20%. Fibrates were the most commonly used 
hypolipidaemic agents (48%), while 31% of patients 
received combination therapy with a fibrate and statin. 
Statin monotherapy was used in 11% of patients and a few 
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patients were treated with niacin or required no drug therapy. 
The treated cholesterol was 5.7 ± 2.4 mmol/1, with plasma 
triglycerides of 2.7 ± 1.9 mmol/1. 
Conclusions. Dysbetalipoproteinaemia is a highly atherogenic 
disorder and is extremely responsive to therapy. A significant 
proportion of dysbetalipoproteinaemia locally is caused by 
the apoE2 (Arg145~Cys) mutation and is therefore 
dominantly inherited. This mutation is particularly prevalent 
in the black community where dysbetalipoproteinaemia may 
be undiagnosed in many patients. Patients with severe mixed 
hyperlipidaemia or clinical stigmata of dyslipidaemia should 
be assessed at a lipid clinic for a specific diagnosis and 
initiation of therapy. 
S Afr Med J 2002; 92: 892-897. 
The Groote Schuur Hospital lipid clinic is one of two tertiary 
referral lipid clinics in the Western Cape province of South 
Africa. Approximately 300 new patients with a wide variety of 
lipid disorders are seen every year. The clinic aims to make a 
specific diagnosis for every patient by taking a full family 
history, carefully examining for clinical signs of dyslipidaemia 
and by performing investigations that will further assist in the 
identification of monogenic (so-called 'major gene defects') 
disorders of lipid metabolism. Such disorders cause severe 
premature atherosclerosis in the absence of other risk factors1" 
and require family screening so that early preventive therapy 
can be instituted.' Apart from the routine lipid profile 
comprising fasting triglycerides, total cholesterol, high-density 
cholesterol and calculated low-density cholesterol, additional 
investigations (electrophoresis, ultracentrifugation and 
genotyping) may be done as necessary to confirm or exclude 
diagnoses suspected clinically. 
Dysbetalipoproteinaemia is a monogenic disorder of 
lipoprotein metabolism. It is caused by mutations that disrupt 
the binding of apolipoprotein E (a poE) to lipoprotein receptors. 
Although uncommon, with an estimated incidence of 1 - 5 per 
5 000 in the USA,' it is an important disorder to recognise 
because of its extreme atherogenicity and the often very 
favourable response to therapy. Dysbetalipoproteinaemic 
patients have a mixed hyperlipidaemia, with elevation of both 
cholesterol and triglycerides. The ratio of cholesterol to 
triglyceride in the plasma is often around 2:1 in molar terms, 
but may be very variable. This disorder is also known as type 
III hyperlipidaemia, remnant removal disease, and broad beta 
disease or familial dysbetalipoproteinaemia. 
Triglyceride-rich lipoproteins are synthesised in the gut as 
chylomicrons (CM) after a meal and by the liver as very-low-
density lipoproteins (VLDL). Triglyceride-rich lipoproteins 
contain proportionally little cholesterol and their main function 
is to transport triglycerides in the blood. Endothelium-bound 
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lipoprotein lipase (LPL) hydrolyses some of the triglyceride 
content of circulating triglyceride-rich lipoproteins and smaller 
particles called remnants are formed. Remnants are 
subsequently taken up by the liver where they are further 
metabolised. The uptake of remnants by the liver is mediated 
through the low-density lipoprotein receptor (LDLR) and the 
low-density lipoprotein receptor-related protein (LRP) with 
heparan sulfate proteoglycans (HSPG) acting as a co-factor for 
LRP as well as mediating independent uptake of remnants.46 
ApoE is the ligand with which remnants bind to their hepatic 
receptors. Remnant particles acquire apoE in the circulation 
mainly through transfer of apoE from high-density lipoproteins 
(HDL). In dysbetalipoproteinaemia, binding of apoE to hepatic 
receptors is either defective' because of mutations in a poE, or 
rarely there is apoE deficiency. Fig. 1 gives a schematic 
representation of remnant metabolism. 
Fig. 1. Schematic representation of remnant lipoprotein metabolism. 
Chy/omicrons (CM) from the gut and hepatic VLDL undergo 
triglyceride hydrolysis by lipoprotein lipase (LPL) and chylomicron 
remnants (CMr) and VLDL remnants (VLDLr) are formed. VLDLr 
can be converted to LDL by hepatic lipase (HL) or can be taken up 
directly by the liver as is the case with CMr. ApoE mediates binding 
of remnants to hepatic lipoprotein receptors. The hepatic lipoprotein 
receptors are the LDL receptor (LDLR), the LDL receptor related 
protein (LRP) and heparan sulfate proteoglycans (HSPG). 
At the apoE gene locus three common variants designated 
E2, E3 and E4'·8 are found, resulting in three homozygous 
(E2/E2, e3/E3, e4/E4) and three heterozygous (E2/E3, E2/e4, 
e3/e4) genotypes. The apoE encoded by the three common 
genotypic variants is designated apoE2, E3 and E4. The 
majority of the population has an apoE3/E3 phenotype, while 
about 1% of the population is homozygous for apoE2. ApoE2 
homozygosity is the commonest molecular cause of 
dysbetalipoproteinaemia, making the inheritance recessive. 
There are, however, other apoE mutations that are dominantly 
expressed such as the apoE2 (Arg145~Cys) mutation. In 
apoE2 homozygotes remnants bind poorly to hepatic receptors9 
with delayed clearance from the circulation, but under 
ordinary circumstances their removal is still sufficient to avoid 
hyperlipidaemia. Any stress of the system, by either over-
production (diabetes, alcohol, obesity) of triglyceride-rich 
lipoproteins, decreased receptor expression (hypothyroidism) 
or impaired lipolysis (renal failure) could precipitate 
hyperlipidaemia. Age is a powerful permissive factor for 
dysbetalipoproteinaemia in genetically predisposed 
individuals- there is a delayed penetrance of the phenotype 
so that hyperlipidaemia usually presents in adulthood. It is 
very unusual to see hyperlipidaemia in premenopausal 
females, in whom oestrogen is protective by enhancing 
remnant clearance.10 Hyperlipidaemia in 
dysbetalipoproteinaemic patients not only results from 
impaired remnant clearance, but accumulation of abnormal 
apoE impairs lipolysis of triglycerides in VLDL by LPL,11•12 
reduces the activity of hepatic lipase" and stimulates the 
production of VLDL by the liver. 14 
Dysbetalipoproteinaemia can be diagnosed on clinical 
grounds if the characteristic palmar crease xanthomas (yellow 
discolouration of palmar creases) are seen in the presence of a 
mixed hyperlipidaemia (Fig. 2). Patients may also have 
tuberous, tuba-eruptive and tendon xanthomas, but these 
lesions are not unique to dysbetalipoproteinaemia and are 
frequently absent (Fig. 3). Laboratory confirmation requires 
specialised testing, but there are no universally accepted 
diagnostic criteria. Testing is based either on analysis of apoE, 
usually by genotyping, or on analysis of lipoproteins for their 
composition or electrophoretic properties. Only 42% of patients 
have the characteristic broad-beta band on agarose gel 
electrophoresis,15 which is the most widely available test. 
Electrophoresis of ultracentrifugally isolated lipoprotein 
fractions and the demonstration of abnormally migrating 
VLDL (~-VLDL) is diagnostically more useful. The presence of 
~-migrating lipoproteins in the VLDL fraction (VLDL 
Fig. 2. Palmar crease xanthoma. Yellow infiltration of the palmar 
creases is diagnostic of dysbetalipoproteinaemia. 
ORIGINAL ARTICLES 
Fig. 3. Tuberous xanthoma. Large tuberous xanthoma on the elbows. 
Complete regression was seen on therapy. 
lipoproteins normally migrate into a pre-~ position) explains 
the name of this condition. Dysbetalipoproteinaemic patients 
have cholesterol-enriched VLDL and abnormally high ratios of 
VLDL cholesterol compared with either VLDL or plasma 
triglycerides. Mass ratios of either 0.4216 or 0.3517 have been 
suggested as diagnostic ratios within VLDL, while 0.3018 or 
0.2519 are the proposed criteria when comparing VLDL 
cholesterol with plasma triglycerides. All these tests require 
ultracentrifugation, which is available only in research 
laboratories. The diagnostic accuracy is reduced if 
hyperlipidaemia is only mild or extremely severe.16-19 The 
common a poE alleles are determined by polymerase chain 
reaction (PCR) and restriction fragment length analysis,20 while 
a poE phenotype can be determined by one of several 
isoelectric focusing techniques.'1 
METHODS 
We retrospectively reviewed the records of all 
dysbetalipoproteinaemic patients identified by review of the 
clinical and laboratory databases. VLDL composition was 
analysed after fasted EDTA plasma was adjusted in density 
with potassium bromide and under layered ·below a saline/ 
EDTA cushion. Ultracentrifugation was performed for 16 
hours in a Beckman SW40 rotor at 100 000 g. The supernatant 
was recovered and lipid concentrations were analysed using 
standard enzymatic methods. All ratios are expressed in terms· · 
of mass. A poE genotyping was performed according to a 
previously reported method.'° Clinical information was 
incomplete on some patients seen before 1985. We based the 
diagnosis of dysbetalipoproteinaemia on the presence of one of 
the following criteria: (i) a mixed hyperlipidaemia (total 
cholesterol > 7 mmol/1 and plasma triglycerides > 3 mmol/l) 
with a ratio of cholesterol in VLDL to triglyceride in VLDL of 
2 0.42 or a r~tio of cholesterol in VLDL to plasma triglyceride 
of 2 0.30; and (ii) a mixed hyperlipidaemia associated with 
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homozygosity for E2 or the presence of one of the other a poE 
mutations associated with dysbetalipoproteinaemia. 
Continuous variables are given as mean ± standard 
deviation (SD), and significance was tested using the unpaired 
t-test or Fisher's exact test. A P-value < 0.05 was taken as 
statistically significant. 
RESULTS 
We identified a total of 105 patients who fulfilled the above 
criteria. Our first patient was diagnosed clinically in 1969 but 
the diagnosis has subsequently been confirmed by 
ultracentrifugation and genotyping. Follow-up on the 91 
patients who returned at least once to the clinic after their 
initial consultation represents approximately 490 patient-years. 
The reasons for referral to the lipid clinic are listed in Table I. 
Most patients with cutaneous xanthoma were initially referred 
to dermatologists. Other modes of presentation included 
symptomatic atherosclerotic disease, incidental discoveries and 
pancreatitis. Patients are further characterised in Table II 
according to the clinical features at presentation. 
Table I. Indication for referral of patients with dysbetalipo-
proteinaemia to the lipid clinic 
Indication 
Secondary prevention 












Dysbetalipoproteinaemia occurred in all racial groups. We 
diagnosed dysbetalipoproteinaemia in 11% of all black patients 
referred to the lipid clinic, making this diagnosis the 
commonest genetic hyperlipidaemia seen in this population 
group at our clinic. 
We found palmar crease xanthoma in 21/101 patients (20%), 
and 12 of 21 patients (57%) with palmar crease xanthomas also 
had tuberous and/ or tuba-eruptive xanthomas. Seven patients 
had cutaneous xanthomas without palmar crease infiltration. 
Lipid deposition in the skin regressed with effective lipid-
lowering therapy in all our patients. Thirteen patients (13%) 
had tendon xanthomas, found exclusively in the Achilles 
tendons. Clinical stigmata of dyslipidaemia were found with 
comparable frequency in both sexes. 
Of 101 patients for whom sufficient clinical data were 
available, 37 (37%) had evidence of ischaemic heart disease 
(IHD) at presentation as witnessed by a convincing history of 
angina pectoris, previous myocardial infarction, coronary 
artery bypass surgery in the past or percutaneous coronary 
revascularisation. During follow-up another 10 patients were 
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Table II. Clinical characteristics of dysbetalipoproteinaemic patients at the lipid clinic 
Males 
Age 
Number of patients 55 
Mean age at presentation (± SD) 46.3 (10.6) 
Age range (years) 6-65 
Lipid values 
Number of patients 55 
Presentation TC (mrnol/D 11.9 (5.9) 
Presentation TG (mmol/l) 9.2 (11.1) 
Number of patients 45 
Best TC (mmol/1) 5.5 (2.0) 
Best TG (rnmol/1) 2.8 (2.2) 
Secondary causes 
Number of patients 55 
Diabetes (N) 17 
Hypothyroidism (N) 
Renal disease (all) (N) 2 
Alcohol (N) 4 
Complications 



















































SD ==: standard deviation; TC :::: total cholesterol; TG ::::: triglycerides; IHD = ischaemic heart disease; PVD = peripheral vascular disease; NS = not statistically significant, P > 0.05. 
diagnosed with IHD, resulting in a prevalence of 47%. Twenty 
patients (20%) had peripheral vascular disease diagnosed 
based on claudication and abnormalities on clinical 
examination or a history of surgery for obstructive peripheral 
vascular disease. Peripheral vascular disease was found 
significantly more frequently in females than males. 
Co-morbidity is frequent in patients with 
dysbetalipoproteinaemia. The prevalence of diabetes was 34%, 
and 55% of patients were hypertensive. Hypothyroidism was 
identified in four patients and hyperlipidaemia improved 
markedly on replacement therapy with thyroxine. In 4 patients 
there was significant alcohol abuse, while 2 patients had the 
nephrotic syndrome. Another 5 patients had significant other 
renal disease. 
The mean total cholesterol at presentation was 12.0 
± 5.5 mmol/1 with a maximum of 34.3 mmol/l. Plasma 
triglycerides had greater variability with a mean of 8.3 ± 9.8 
mmol/1 (median 5.1 mmol/l) and a maximum of 63.2 mmol/l. 
Ultracentrifugal data are available for 104 patients. The mean 
ratio of cholesterol to trig1ycerides within VLDL was 0.52 
± 0.17, with the mean ratio of VLDL cholesterol to plasma 
triglycerides being 0.33 ± 0.09. In 57 patients (54%) both ratios 
were diagnostically elevated, 27 patients (26%) had a diag-
nostic ratio within VLDL only, while in 10 patients (10%) only 
the ratio related to plasma triglycerides was positive. We 
diagnosed dysbetalipoproteinaemia in 10 patients (10%) with a 
mixed hyperlipidaemia who had non-diagnostic 
ultracentrifugation but an appropriate genotype. 
A poE genotyping data are available on all 105 patients. Fifty 
patients (48%) are homozygous for £2, while 22 (21 %) have 
ApoE2 (Argl45~Cys). This mutation causes 
dysbetalipoproteinaemia in an autosomal-dominant fashion 
with incomplete penetrance.22 0ne patient (1 %) has apoE2 
(Lys146~Gln). In 32 patients (30%) we diagnosed dysbetalipo-
proteinaemia on phenotypic grounds, but have not as yet 
defined the underlying abnormality in a poE. 
In 84 patients we had sufficient follow-up data to analyse 
response to treatment. We calculated response to therapy by 
comparing the best lipid values obtained during follow-up 
with the patient's lipid values in the untreated state. A mean 
reduction in total cholesterol of 6.2 ± 5.5 mmol/1 (52%) and in 
plasma triglycerides of 5.5 ± 8.6 mmol/1 (66%) was obtained. 
The best on-treatment lipid values were a cholesterol of 5.7 
± 2.4 mmol/1, with plasma triglycerides of 2.7 ± 1.9 mmol/l. 
All patients were given appropriate dietary advice and 
encouraged to exercise regularly. Conditions precipitating 11m 
hyperlipidaemia such as hypothyroidism and diabetes were 
treated aggressively before lipid-lowering drug therapy was 
initiated. Five patients (6%) required no other therapy to 
control their lipids. Two (2%) were controlled on therapy with 
niacin alone, while 40 (48%) were treated with a fibrate. Nine 




(31 %) received a combination of a fibrate and statin. Two 
patients (2%) were treated with a combination of a fibrate and 
niacin. 
DISCUSSION 
Our series of dysbetalipoproteinaemic patients is one of the 
largest reported from a single institution. Patients were selected 
using stringent phenotypic criteria in combination with 
genotypic information. A direct comparison of our experience 
with that previously reported3•23.26 is not always possible, as the 
standards used to diagnose dysbetalipoproteinaemia over the 
years have shifted from a purely clinical diagnosis" to a more 
laboratory-based diagnosis. 
As women in general only present after menopause, they are 
on average about 10 years older than men at presentation.'·"·" 
We also noted significantly earlier presentations in men than in 
women, but compared with another large series," the 
difference was less impressive. Although our patients were 
generally older at presentation (48.8 years v. 43.8 years24), the 
reduced age gap between the sexes is mainly accounted for by 
older age at presentation in men locally (39.8 years v. 46.3 years"). 
The older age of presentation we report is probably due to the 
higher proportion of patients seen for secondary prevention. 
Furthermore, in a few cases there were substantial delays 
between the discovery of hyperlipidaemia and the referral of 
patients. 
Untreated lipid values previously reported are similar to 
those we observed. Morganroth et al.24 reported a mean total 
cholesterol of 11.7 mmol/1 with plasma triglycerides of 
7.9 mmol/1. In a pooled series of 185 patients' the mean 
reported total cholesterol was 11.7 mmol/1 with plasma 
triglycerides of 6.4 mmol/1. 
The frequency of clinical stigmata of lipid disorders is very 
variable, reflecting varying referral practices and diagnostic 
criteria. Some earlier series" included only patients with 
xanthomas. The reported incidence of palmar crease 
xanthomas ranges from 23% to 72%. However, in all series 
palmar and cutaneous xanthomas occur with approximately 
equal frequencies, with tendon xanthomas being the least 
common clinical manifestation of dysbetalipoproteinaemia. 
Dysbetalipoproteinaemia is a highly atherogenic condition. 
As dysbetalipoproteinaemic patients usually only become 
hyperlipidaemic in adulthood, the exposure interval from 
hyperlipidaemia to the onset of atherosclerotic complications 
may be as short as a decade only. This is in marked contrast to 
patients with familial hypercholesterolaemia, who are 
hyperlipidaemic from birth and where untreated males on 
average have a first myocardial infarction at 43 years of age.27 
In our experience dysbetalipoproteinaemic patients also face 
the added risk of hypertriglyceridaemic pancreatitis. Peripheral 
vascular disease is believed to be more prevalent in this 
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condition than in other dyslipidaemias. In our experience the 
high frequency of peripheral vascular disease among females 
is of interest as it has not been described previously, although 
most case series did not differentiate clinical manifestations 
according to sex. Peripheral vascular disease and diabetes were 
strongly associated in both sexes. 
Homozygosity for the £2 allele is the molecular defect in 
most patients' but in our series the apoE2 (Arg 145--7Cys) 
mutation accounts for 21% of all cases in contrast to its very 
rare occurrence in other lipi~ clinics. The apoE2 (Arg145--7Cys) 
mutation is particularly prominent in the black patients at our 
clinic. Similar regional clusterings of mutations causing 
dysbetalipoproteinaemia, possibly secondary to founder 
effects, have also been described in Spain28 and in the 
Netherlands.29 
Marked responsiveness to dietary and drug therapy is 
characteristic of dysbetalipoproteinaemia3•23•30 and excellent 
control of hyperlipidaemia was achieved in nearly all our 
patients. Fibrates are the initial drug of choice as they are 
generally very effective and also have a cost advantage over 
statins in the public health sector. 
We suspect that the diagnosis of dysbetalipoproteinaemia is 
frequently overlooked, especially in blacks who may have an 
additional burden of apoE2 (Argt145--7Cys) to the generally 
accepted prevalence of 1 - 2% for apoE2/E2. Making the correct 
diagnosis will allow patients to receive appropriate therapy 
that will result in marked improvement in their prognosis. The 
children of parents with the apoE2(Argt145--7Cys) mutation 
have a 50% chance of inheriting the mutation and regular lipid 
screening is advised for carriers of the gene. 
Patients with severe hypercholesterolaemia require 
assessment of a fasting lipid profile' to distinguish between 
isolated hypercholesterolaemia and mixed hyperlipidaemia. 
We recommend that all patients with severe mixed 
hyperlipidaemia, or clinical signs such as palmar crease 
xanthomas and cutaneous or tendon xanthomas, or strong 
family histories of premature vascular disease, be referred to a 
lipid clinic to establish a diagnosis. Apart from benefiting 
patients there is also considerable scientific interest in further 
studying this condition in South Africa. Further studies are also 
required to determine the true frequency of the apoE2 
(Argt145--7Cys) mutation in the various population groups. 
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INTRAPARTUM-RELATED BIRTH 
ASPHYXIA IN SOUTH AFRICA-
LESSONS FROM THE FIRST 
NATIONAL PERINATAL CARE 
SURVEY 
E J Buchmann, R C Pattinson, N Nyathikazi 
Background. The recent amalgamation of data by users of the 
Perinatal Problem Identification Programme (PPIP) 
throughout South Africa has culminated in the publication 
of the Saving Babies report. 
Objectives. To determine the absolute rate of death from 
intrapartum-related birth asphyxia, and the contribution of 
intrapartum-related asphyxia to total perinatal mortality in 
South African hospitals, and to identify the primary 
obstetric causes and avoidable factors for these deaths. 
Methods. The amalgamated PPIP data for the year 2000 were 
obtained from 27 state hospitals (6 metropolitan, 12 town 
and 9 rural) in South Africa. In PPIP-based audit, all 
perinatal deaths are assigned primary obstetric causes and 
avoidable factors, and these elements were obtained for all 
deaths resulting from intrapartum-related birth asphyxia. 
Results. There were 123 508 births in the hospitals surveyed, 
with 4 142 perinatal deaths among infants 2': 1 000 g, giving 
a perinatal mortality rate of 33.5/1 000 births. The perinatal 
mortality rate from intrapartum-related birth asphyxia was 
4.8/1 000 births. The most frequent avoidable factors were 
delay by mothers in seeking attention during labour 
(36.6%), signs of fetal distress interpreted incorrectly 
(24.9%), inadequate fetal monitoring (18.0%) and no 
response to poor progress in labour (7.0%). The perinatal 
mortality rates for metropolitan, town and rural areas were 
30.0, 39.4 and 30.9/1 000 births respectively. The 
contribution of intrapartum-related birth asphyxia to 
perinatal mortality in these areas was 10.8%, 16.7% and 
26.4% respectively. 
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